A phase 1, first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending intravenous dose study of VGL101, a novel TREM2 agonist, in healthy adult volunteers (HVS)
20230 citationsJournal Articlebronze Open Access
Field-Weighted Citation Impact: 0.00
A phase 1, first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending intravenous dose study of VGL101, a novel TREM2 agonist, in healthy adult volunteers (HVS) | Researchclopedia